« We are Passionate about Transforming the Lives of our Patients » This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.

August 5, 2021 NLS Pharmaceutics to Participate in the Canaccord Genuity 41st Annual Growth Conference link Issuer Direct STANS, SWITZERLAND / ACCESSWIRE / August 5, 2021 / NLS Pharmaceutics Ltd. (NASDAQ:NLSP, NLSPW) ("NLS" or the "Company"), a Swiss clinical-stage pharmaceutical company focused on the discovery and development of innovative therapies for patients with rare and complex central nervous system disorders, announces that Alex Zwyer, Chief Executive Officer and Co-Founder, is scheduled to present at the Canaccord Genuity 41st Annual Growth Conference being held virtually August 10-12, 2021. Presentation Details: Date: Thursday, August 12, 2021 Time: 10:00 AM ET The presentation will be webcast live and can be accessed by clicking this link, and will also be available for replay on Company's website at https://nls-pharma.com/ About NLS Pharmaceutics Ltd. NLS Pharmaceutics Ltd. is a Swiss-based clinical-stage biopharmaceutical company led by an experienced management team with a track record of developing and repurposing product candidates to treat rare and complex central nervous system disorders. The Company's lead product candidate, Quilience® is a proprietary extended-release formulation of mazindol (mazindol ER), and is being developed for the treatment of narcolepsy. Mazindol is a triple monoamine reuptake inhibitor and partial orexin-2 receptor agonist, which was used for many years to treat patients diagnosed with narcolepsy in compassionate use programs. NLS completed a phase 2 study in the U.S. evaluating NolazolÒ (mazindol controlled-release) in adult subjects with ADHD. The study met all primary and secondary endpoints and was well-tolerated. Quilience has received Orphan Drug Designations both in the U.S. and in Europe for the treatment of narcolepsy. Corporate contact Alex Zwyer, CEO: +41 41 618 80 00 Investor Relations contact Cindy Rizzo: +1 908-229-7050 www.nlspharma.com SOURCE: NLS Pharmaceutics AG View source version on accesswire.com: https://www.accesswire.com/658361/NLS-Pharmaceutics-to-Participate-in-the-Canaccord-Genuity-41st-Annual-Growth-Conference This website uses cookies for analysis. You can find exact details in our privacy policy. No thank youOk Partnerships Contact NLS Pharmaceutics AG Alter Postplatz 2 CH-6370 Stans NW Switzerland P: +41 41 618 80 00 F: +41 41 618 80 09 contact@nls-pharma.com About NLS Science News Investors About Contact Legal Privacy Policy Terms and Conditions Cookie Policy Follow us ©2021 NLS Pharmaceutics. All rights reserved.